Tuesday, November 20, 2018 10:20:20 AM
November 20, 2018
A third quarter financial report attesting to a solid foundation for long-term growth might as well be the catalyst, poised to trigger a turnaround in GT Biopharma Inc (OTCMKTS:GTBP) sentiments and prospects. Investor confidence in the stock had hit all-time lows depicted by declining share price and market price.
GT BIOPHARMA PRICE ANALYSIS
However, the stock has bounced back on the management team reiterating the company’s long-term prospects and growth metrics. Changes to the leadership team as well as the execution of critical preclinical, clinical, and regulatory milestones are the latest catalysts strengthening investor confidence on GT Biopharma.
The stock has since bounced back from below $1 a share mark, after feeling the full effects of short sellers for the better part of the year. The Chief Executive Officer, Raymond Urbanski, reiterating that the company is in a transitional phase appears to have reinvigorated investor interest in the stock.
While the stock is still engulfed in a long-term bear trend, all indication is that a turnaround in the long-term direction of trade may be in play. The stock faces immediate resistance at the $1.50 a share level on its way back to a critical $1.50 to $2.50 trading range.
After the recent plunge lower, the stock needs to bounce back to the trading range to avert suggestions of a further slide. A rally followed by a close above the $2.50 level, should bring to an end a sell-off wave that had plunged the stock to all-time lows.
ABOUT GT BIOPHARMA
GT Biopharma is a clinical-stage biopharmaceutical company that develops and commercializes novel immune-oncology products. The company develops its products using proprietary Tri-specific Killer Engager, Tetra Specific Killer Engage, and antibody-drug conjugate technology platforms. The company is currently working on OXS-1550 a fusion protein-drug that targets cancer cells expressing the CD19 receptor.
CLINICAL PROGRAM MILESTONES
GT Biopharma continues to show signs of bottoming out from all-time lows at the back of a number of milestones that affirms its long-term prospects. For starters, the company has received an FDA clearance that paves the way for it to commence the first-in-human Phase 1 study of GTB-1550 for the treatment of acute myelogenous leukemia.
The clinical stage biopharmaceutical company is also fresh from announcing positive preclinical data on two candidate drugs for the treatment of ovarian, head and neck cancers. The company also entered into an agreement with a major pharmaceutical company and consequently initiated a preclinical combination trial, between GTB 1550 and multibillion-dollar oncology drug.
“We have made significant progress in building a solid foundation for the Company in what we believe is an important transitional phase for GT Biopharma. The additions and changes to the leadership team and execution of key preclinical, clinical and regulatory milestones are a testament to this progress,” commented said Mr. Urbanski.
WIDENING NET LOSS
GT Biopharma finds itself in a precarious position even on making impressive strides in the development of its novel treatment for addressing different types of cancer. Net loss in the recent quarter surged to (-$235,783,000) or (-$4.70) per diluted share, compared to a net loss of (-$130, 625,000) as of the same quarter last year. For the nine months ended September 30, 2018, the company’s net loss stood at (-$254, 955,000) compared to a net loss of (-$138, 146,000) reported the same period last year.
The company’s total deficit currently stands at (-$524,453,000) with a cash balance of $1.2 million. Amidst the dire financial position the company finds itself in, the chief executive officer insists they are doing all they can to navigate through the challenging times.
“However, as we navigate through this phase, we certainly face challenges, including ensuring we are properly funded and have the right team in place to propel the Company to our next phase of growth. Successfully completing financing and bolstering our management team and Board in the near term remains a priority,” said Mr. Urbanski.
BOTTOM LINE
GT Biopharma has made impressive strides in the development of key cancer treatments poised to strengthen its long-term prospects. The fact that the company has received FDA clearance to commence in human trials is a significant milestone.
The management has also reaffirmed commitment to securing additional capital. The focus is on accelerating the execution of the company’s growth strategy and advancing clinical development programs in a bid to drive shareholder value.
That said, the stock needs to rise and stabilize above the $1.50 mark for one to consider it a long-term play.
We will be updating our subscribers as soon as we know more. For the latest updates on GTBP, sign up below!
https://insiderfinancial.com/gt-biopharma-inc-otcmktsgtbp-fda-clinical-trials
Recent GTBP News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/16/2024 08:05:21 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/17/2024 08:26:23 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 06/13/2024 08:14:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/07/2024 09:25:06 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 05/24/2024 12:31:08 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/23/2024 10:04:59 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 10:02:41 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 09:00:40 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:46:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 05:15:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 08:30:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/04/2023 10:00:11 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 11/06/2023 10:25:12 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 11/06/2023 10:23:32 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/06/2023 10:21:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/01/2023 01:00:37 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 10/27/2023 09:23:48 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM